Stock Events

Stock Events

Mind Medicine 

€0.000000
949
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q1 2026
Next
-0.61
-0.54
-0.48
-0.42
Expected EPS
-0.487103487
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BGHM.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.84B
Compass Pathways operates in the psychedelic medicine space, focusing on psilocybin therapy for depression, directly competing with Mind Medicine's psychedelic-based treatments.
AtaiBeckley
ATAI
Mkt Cap1.91B
ATAI Life Sciences is a biotech company with a focus on psychedelic and non-psychedelic compounds for mental health, making it a direct competitor in the psychedelic medicine market.
GH Research
GHRS
Mkt Cap1.85B
GH Research is developing a novel therapeutic approach for mental health disorders using 5-MeO-DMT, competing in the same space as Mind Medicine's psychedelic-based treatments.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness is involved in the development of psychedelic therapies, including psilocybin and MDMA, positioning it as a competitor in the psychedelic medicine industry.
Revive Therapeutics
RVVTF
Mkt Cap8.71M
Revive Therapeutics is exploring the use of psychedelics for the treatment of mental illness and addiction, competing in the same therapeutic space as Mind Medicine.
TripAdvisor
TRIP
Mkt Cap1.66B
Red Light Holland is focused on the production, growth, and sale of a premium brand of magic truffles, entering the broader market of psychedelic substances that Mind Medicine is also targeting.
Noveris Health Sciences
MYCOF
Mkt Cap117.1M
Mydecine Innovations Group is a biotech company focusing on the development of psychedelic therapies, making it a competitor in the emerging field of psychedelic medicine.

About

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Show more...
CEO
Mr. Robert Barrow
Employees
57
Country
Canada
ISIN
CA60255C1095

Listings

MU
DE
MMQ0.MU
STU
DE
MMQ0.STU
STU
DE
BGHM.STU
F
DE
MMQ0.F

0 Comments

Share your thoughts

FAQ

What is Mind Medicine stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Mind Medicine stocks are traded under the ticker BGHM.STU.
When is the next Mind Medicine earnings date?▼
Mind Medicine is going to release the next earnings report on August 06, 2026.
What were Mind Medicine earnings last quarter?▼
BGHM.STU earnings for the last quarter are -0.61 EUR per share, whereas the estimation was -0.42 EUR resulting in a -44.27% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Mind Medicine have?▼
As of July 09, 2026, the company has 57 employees.
In which sector is Mind Medicine located?▼
Mind Medicine operates in the Health & Wellness sector.
When did Mind Medicine complete a stock split?▼
Mind Medicine has not had any recent stock splits.
Where is Mind Medicine headquartered?▼
Mind Medicine is headquartered in New York, Canada.